Urinary Trypsin Inhibitor Fragment Peptide | PLAU peptide

Urinary Trypsin Inhibitor Fragment

Cat. Num. AAA658852

• Gene Names: PLAU; ATF; QPD; UPA; URK; u-PA; BDPLT5
• Purity: Highly Purified; ~95%. Purified by HPLC.
• Synonyms: Urinary Trypsin Inhibitor Fragment; PLAU peptide

• Host: Synthetic peptide
• Purity/Purification: Highly Purified; ~95%. Purified by HPLC.
• Form/Format: Supplied as a lyophilized powder.

• Sequence (linear): Arg-Gly-Pro-Cys-Arg-Ala-Phe-Ile
• Preparation and Storage: Lyophilized powder may be stored at 4 degree C for short-term only. Stable for 12 months at -20 degree C. Reconstitute to nominal volume (see reconstitution instructions for peptides) and store at -20 degree C. For maximum recovery of product, centrifuge the original vial prior to removing the cap. Further dilutions can be made in assay buffer.

Product Categories/Family for PLAU peptide

Molecular Biology; MB-Peptides

NCBI and Uniprot Product Information

• NCBI GI #: 222537759
• NCBI GeneID: 5328
• NCBI Accession #: NP_001138503.1
• NCBI GenBank Nucleotide #: NM_001145031.1
• UniProt Accession #: P00749; Q15844; Q16618; Q53XS3; Q5SWW9; Q969W6; B4DPZ2
• Molecular Weight: 48,507 Da
• NCBI Official Full Name: urokinase-type plasminogen activator isoform 2
• NCBI Official Synonym Full Names: plasminogen activator, urokinase
• NCBI Official Symbol: PLAU
• NCBI Official Synonym Symbols: ATF; QPD; UPA; URK; u-PA; BDPLT5
• NCBI Protein Information: urokinase-type plasminogen activator; U-plasminogen activator; plasminogen activator, urinary
• UniProt Protein Name: Urokinase-type plasminogen activator
• Protein Family: Urokinase-type plasminogen activator
• UniProt Gene Name: PLAU
• UniProt Synonym Gene Names: U-plasminogen activator; uPA
• UniProt Entry Name: UROK_HUMAN

NCBI Description

This gene encodes a serine protease involved in degradation of the extracellular matrix and possibly tumor cell migration and proliferation. A specific polymorphism in this gene may be associated with late-onset Alzheimer's disease and also with decreased affinity for fibrin-binding. This protein converts plasminogen to plasmin by specific cleavage of an Arg-Val bond in plasminogen. Plasmin in turn cleaves this protein at a Lys-Ile bond to form a two-chain derivative in which a single disulfide bond connects the amino-terminal A-chain to the catalytically active, carboxy-terminal B-chain. This two-chain derivative is also called HMW-uPA (high molecular weight uPA). HMW-uPA can be further processed into LMW-uPA (low molecular weight uPA) by cleavage of chain A into a short chain A (A1) and an amino-terminal fragment. LMW-uPA is proteolytically active but does not bind to the uPA receptor. Alternatively spliced transcript variants encoding different isoforms have been found for this gene. [provided by RefSeq, Feb 2009]

Uniprot Description

Function: Specifically cleaves the zymogen plasminogen to form the active enzyme plasmin.

Catalytic activity: Specific cleavage of Arg-|-Val bond in plasminogen to form plasmin.

Enzyme regulation: Inhibited by SERPINA5. Ref.17 Ref.22

Subunit structure: Found in high and low molecular mass forms. Each consists of two chains, A and B. The high molecular mass form contains a long chain A which is cleaved to yield a short chain A. Forms heterodimer with SERPINA5. Binds LRP1B; binding is followed by internalization and degradation. Interacts with MRC2. Interacts with PLAUR. Ref.20 Ref.21

Subcellular location: Secreted.

Tissue specificity: Expressed in the prostate gland and prostate cancers. Ref.23

Post-translational modification: Phosphorylation of Ser-158 and Ser-323 abolishes proadhesive ability but does not interfere with receptor binding.

Involvement in disease: Quebec platelet disorder (QPD) [MIM:601709]: An autosomal dominant bleeding disorder due to a gain-of-function defect in fibrinolysis. Although affected individuals do not exhibit systemic fibrinolysis, they show delayed onset bleeding after challenge, such as surgery. The hallmark of the disorder is markedly increased PLAU levels within platelets, which causes intraplatelet plasmin generation and secondary degradation of alpha-granule proteins.Note: The disease is caused by mutations affecting the gene represented in this entry. Ref.24

Pharmaceutical use: Available under the name Abbokinase (Abbott). Used in Pulmonary Embolism (PE) to initiate fibrinolysis. Clinically used for therapy of thrombolytic disorders.

Sequence similarities: Belongs to the peptidase S1 family.Contains 1 EGF-like domain.Contains 1 kringle domain.Contains 1 peptidase S1 domain.